Form 4: Myriad Genetics Executive Receives Stock Grant

Shereen Solaiman, Chief People Officer at Myriad Genetics, reports the acquisition of 41,042 shares of common stock through a restricted stock unit grant.

Summary

• On March 14, 2024, Shereen Solaiman, Chief People Officer of Myriad Genetics Inc., acquired 41,042 shares of common stock.
• These shares were obtained through a grant of time-based restricted stock units under the company's 2017 Employee, Director and Consultant Equity Incentive Plan.
• The restricted stock units vest in three equal annual installments, starting on the first anniversary of the grant date.
• Following this transaction, Solaiman directly owns 55,790 shares of Myriad Genetics common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine executive compensation event, which is neutral to slightly positive as it incentivizes management.

Positives

• The grant of restricted stock units aligns the executive's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and contribution to Myriad Genetics.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Stock grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Illumina, Inc. and Thermo Fisher Scientific also utilize stock grants as part of their executive compensation plans.
• The vesting schedule of three years is also standard practice to ensure long-term commitment.

Stakeholder Impact

• The stock grant could have a minor positive impact on shareholder sentiment as it aligns executive interests with company performance.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates